Drugs / BIIB068
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02829541 | Aug → Dec 2016 | systemic lupus erythematosus | Biogen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB068 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02829541 ↗ |
| Action | Inhibit | “BIIB068, a Bruton's tyrosine kinase inhibitor” NCT02829541 ↗ |
| Route | Oral | “single oral doses of BIIB068 in healthy participants” NCT02829541 ↗ |